Search EdNeuro Page
Search EdNeuro Page
The search found 24 results in 0.028 seconds.
Results of the FOCUS clinical trial led by Professor Martin Dennis and Professor Gillian Mead (Centre for Clinical Brain Sciences), which tested the efficacy of fluoxetine to improve physical ability in stroke patients indicated that there was no improvement in patients given this drug compared with patients given a placebo drug.
Organised but the Centre for Dementia Prevention, this 5 day course is a unique opportunity for a cross-disciplinary tour of methodology in the field of Alzheimer’s Disease Research.
Congratulations to Prof Rustam Al-Shahi Salman (Centre for Clinical Brain Sciences) and colleagues who have recently published two studies published in The Lancet and The Lancet Neurology, indicating that people who suffer a brain haemorrhage can take common medicines without raising their risk of another stroke.
On Wednesday 28 June 2017, members of the University of Edinburgh's Stroke Research Group (SRG), both past and present, gathered to celebrate 30 years of stroke research in Edinburgh. There was an excellent turn out for the celebration, including Professor Emeritus Charles Warlow, and Peter Sandercock presented a nostalgic walk down memory lane before cutting the cake.
The Centre for Clinical Brain Sciences (CCBS) was profiled in The Lancet, in an article outlining the structure and research focus of the Centre.
Professors Joanna Wardlaw (Centre for Clinical Brain Sciences, University of Edinburgh), Karen Horsburgh (Centre for Neuroregeneration, University of Edinburgh) and Rhian Touyz (Institute of Cardiovascular & Medical Sciences, University of Glasgow) are guest editors on the recently released Clinical Science special edition on small vessels, dementia & chronic disease.
The pioneering dementia ‘buddy scheme’ headed by Dr Chris Henstridge (Centre for Discovery Brain Sciences) and co-ordinated by Lilian Kennedy (Social Anthropology) was recently featured on BBC News. The scheme pairs university researchers with people who are living with dementia to enable them to learn from each other.
Professor Brian Walker, Professor Jonathan Seckl and Dr. Scott Webster (all Centre for Cardiovascular Sciences) have developed a drug, Xanamem, that has just entered Phase II clinical trials and been administered to the first patient by Actinogen Medical in Australia.
The objective of this course is to provide an introduction to the management of randomised control trials (RCTS), by giving an overview of the standard processes and legal requirements necessary to undertake clinical research.
The University of Edinburgh is joining with five other institutions to form the UK Dementia Research Intitute (UK DRI), along with charity partners Alzheimer's Society and Alzheimer's Research UK.